+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemophilia B Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5464153
Hemophilia B pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Hemophilia B pipeline drugs and companies” presents key-decision makers with critical insights into Hemophilia B pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Hemophilia B pipeline Drug Snapshot, 2021

The Hemophilia B pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Hemophilia B. In addition to recent status, overview of drugs is included in the study. Wide range of Hemophilia B drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Hemophilia B drug development pipeline by phase

The Hemophilia B pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Hemophilia B pipeline candidates is provided in the report enables you to understand timetable developments in Hemophilia B therapeutic area.

Hemophilia B pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Hemophilia B pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Hemophilia B research study. Companies looking to partner with other players are also detailed in the report.

Hemophilia B- mechanism of action of pipeline candidates

Hemophilia B pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Hemophilia B companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Hemophilia B drug administration.

Hemophilia B Drugs- Preclinical and Clinical Trials

This chapter in Hemophilia B preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Hemophilia B product area. Preclinical and clinical trial details of pipeline candidates for Hemophilia B are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Hemophilia B companies and Profiles

Companies developing Hemophilia B pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Hemophilia B Market Developments

The report presents the recent news and developments in the Hemophilia B pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Hemophilia B R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Hemophilia B pipeline drugs and clinical trials
  • Identify Hemophilia B drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Hemophilia B drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Hemophilia B pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Hemophilia B pipeline news, developments and insights

Scope of the Report

  • Disease overview including Hemophilia B symptoms, widely used treatment options, companies and other details are included
  • Hemophilia B Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Hemophilia B pipeline drug count by phase, company and mechanism of action
  • Hemophilia B companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Hemophilia B pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Hemophilia B companies including their business snapshot, business description and Hemophilia B pipelines are included.
  • Recent Hemophilia B market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Hemophilia B Disease overview
2.2 Companies investing in Hemophilia B industry
3 Hemophilia B Pipeline Snapshot, 2021
3.1 Hemophilia B Pipeline Drugs- Dominant phase type
3.2 Hemophilia B pipeline Drugs- Leading Mechanism of Action
3.3 Hemophilia B Pipeline Drugs- Widely researched Route of Administration
3.4 Hemophilia B Pipeline- New Molecular Entity
3.5 Hemophilia B pipeline- Companies, Universities and Institutes
4. Hemophilia B Drug Profiles
4.1 Current Status of Hemophilia B Drug Candidates, 2021
4.2 Hemophilia B Drugs in Development- Originator/Licensor
4.3 Hemophilia B Drugs in Development- Route of Administration
4.4 Hemophilia B Drugs in Development- New Molecular Entity (NME)
5. Hemophilia B Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Hemophilia B Companies and Universities
6.1 Leading Hemophilia B companies researching in drug development
6.2 Leading Hemophilia B Universities/Institutes investing in drug development
7. Hemophilia B News and Deals
7.1 Recent Hemophilia B Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact